We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
+$1.05B
Cap. Flow
-$233M
Cap. Flow %
-3.6%
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$249M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$112M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$71.9M
4
ENDP
Endo International plc
ENDP
+$58M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$53M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$259M
2
BIIB icon
Biogen
BIIB
+$235M
3
AGN
Allergan plc
AGN
+$128M
4
CVS icon
CVS Health
CVS
+$52M
5
CNC icon
Centene
CNC
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 1.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRO icon
101
Spero Therapeutics
SPRO
$69.5M
$6.5M 0.1%
+507,471
New +$5.38M
XENE icon
102
Xenon Pharmaceuticals
XENE
$6.1B
$6.45M 0.1%
634,812
– –
NTLA icon
103
Intellia Therapeutics
NTLA
$1.51B
$6.45M 0.1%
377,600
– –
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$5.81M 0.09%
1,350,655
– –
XFOR icon
105
X4 Pharmaceuticals
XFOR
$377M
$5.42M 0.08%
10,383
– –
ATNX
106
DELISTED
Athenex, Inc. Common Stock
ATNX
$5.27M 0.08%
21,500
– –
NVTA
107
DELISTED
Invitae Corporation
NVTA
$5.2M 0.08%
222,017
-602,532
-73% -$10.6M
VYNE icon
108
VYNE Therapeutics
VYNE
$4.98M 0.08%
+176
New +$4.22M
CTIC
109
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.85M 0.08%
5,000,000
– –
WHWK
110
Whitehawk Therapeutics
WHWK
$181M
$4.68M 0.07%
346,263
– –
TECX
111
Tectonic Therapeutic
TECX
$536M
$4.38M 0.07%
16,549
-4,276
-21% -$782K
RLM
112
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$3.93M 0.06%
1,021,484
– –
NVTR
113
DELISTED
Nuvectra Corporation Common Stock
NVTR
$3.85M 0.06%
350,000
– –
AERI
114
DELISTED
Aerie Pharmaceuticals
AERI
$2.75M 0.04%
58,000
-814,100
-93% -$35.8M
KALV
115
DELISTED
KalVista Pharmaceuticals
KALV
$2.59M 0.04%
+90,500
New +$1.96M
KRYS icon
116
Krystal Biotech
KRYS
$10.7B
$1.95M 0.03%
+59,210
New +$1.4M
MRNS
117
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.66M 0.03%
99,525
-25,000
-20% -$360K
APLS
118
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$1.46M 0.02%
+75,000
New +$1.18M
SNDX icon
119
Syndax Pharmaceuticals
SNDX
$1.7B
$1.11M 0.02%
212,000
– –
SRRA
120
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$542K 0.01%
7,928
-2,500
-24% -$160K
BLRX
121
BioLineRX
BLRX
$12M
$447K 0.01%
1,731
– –
SCTL
122
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$255K ﹤0.01%
48,501
-71,202
-59% -$528K
XYLO
123
DELISTED
Xylo Technologies
XYLO
$44K ﹤0.01%
375
– –
ACIU icon
124
AC Immune
ACIU
$231M
– –
-1,440,000
Closed -$13.6M
AFMD
125
DELISTED
Affimed
AFMD
– –
-32,665
Closed -$1.02M
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2019 Portfolio in Review

As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $233M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Alector worth $247M.

  • OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
  • OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
  • OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
  • OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
  • OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
  • OrbiMed opened 25 new positions and closed 31 in Q1 2019.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.